Semaglutide 8mg ODT (30 day)

Semaglutide 8 mg ODT (30-day supply) is an orally disintegrating tablet formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide mimics the action of endogenous GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety, making it effective for type 2 diabetes management and weight loss. The 8 mg ODT provides a convenient oral alternative to injectable GLP-1 therapies, dissolving rapidly in the mouth and supporting patient adherence. Depending on the clinical protocol, dosing may be weekly or daily, allowing for consistent therapeutic plasma levels over the 30-day period. Clinical trials demonstrate semaglutide’s efficacy in reducing HbA1c, promoting significant weight loss, and improving cardiovascular risk profiles in adults with type 2 diabetes or obesity: Efficacy and weight management outcomes: https://pubmed.ncbi.nlm.nih.gov/32809483/ GLP-1 receptor agonist mechanism of action: https://pubmed.ncbi.nlm.nih.gov/30108389/